For decades, dementia, especially Alzheimer’s disease, was treated as untouchable. Families watched loved ones fade, doctors could offer only reassurance and coping strategies, and research seemed to ...

Please provide your email address to receive an email when new articles are posted on . Cognitive decline is one of the potential adverse effects of cranial radiation therapy in cancer patients. It ...

Brain scan-ss-563672869 Before study initiation, NSE levels were similar for both groups. On Day 3 of the study, the NSE levels were 7.95 ± 2.86 ng/mL for the memantine group and 12.33 ± 7.09 ng/mL ...

MIAMI — A drug that for years has been approved to treat moderate to severe Alzheimer's disease may have a role in improving the cognitive deficits associated with bipolar disorder. In a randomized, ...

Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe AD as ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...

Americans with advanced Alzheimer’s disease soon can try the first treatment proved effective for late stages of the mind-robbing illness. Memantine should be on pharmacy shelves by January under the ...